1.54
+0.16(+11.59%)
Currency In USD
| Previous Close | 1.38 |
| Open | 1.38 |
| Day High | 1.55 |
| Day Low | 1.38 |
| 52-Week High | 4.22 |
| 52-Week Low | 0.61 |
| Volume | 291,928 |
| Average Volume | 1.36M |
| Market Cap | 84.98M |
| PE | -1.05 |
| EPS | -1.47 |
| Moving Average 50 Days | 1.52 |
| Moving Average 200 Days | 1.04 |
| Change | 0.16 |
If you invested $1000 in Prelude Therapeutics Incorporated (PRLD) since IPO date, it would be worth $57.25 as of December 04, 2025 at a share price of $1.5. Whereas If you bought $1000 worth of Prelude Therapeutics Incorporated (PRLD) shares 3 years ago, it would be worth $241.94 as of December 04, 2025 at a share price of $1.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Nov 12, 2025 12:01 PM GMT
Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026 Preclinical
Prelude Therapeutics Announces Strategic Business Update
GlobeNewswire Inc.
Nov 04, 2025 12:05 PM GMT
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously anno
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
GlobeNewswire Inc.
Nov 04, 2025 12:01 PM GMT
Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs) P